The Effect of Rasagiline on Motor and Non-Motor Symptoms in Parkinson’s Disease
Objective: In this study, we aimed to evaluate the effect of rasagiline treatment on motor and non-motor symptoms in patients with Parkinson’s disease (PD). Background:…Levodopa Dose Equivalency for Opicapone and Safinamide
Objective: To provide a levodopa dose equivalency (LED) for opicapone and safinamide. Background: Tomlinson at al., provided a schedule to calculate LED of the different…A pilot study on the efficacy, tolerability and safety of safinamide in elderly Parkinson’s disease patients
Objective: The aim of the study is to evaluate the efficacy, safety and tolerability of SF (50 and 100 mg / day) in elderly patients…Is safinamide helpful in multiple system atrophy?
Objective: To retrospectively review the clinical benefit of safinamide in patients with Multiple System Atrophy. Background: Safinamide is a new monoamine oxidase-B inhibitor, with dopaminergic…Can Safinamide Help to Stabilize Dopaminergic Treatment in Parkinson’s Disease?
Objective: After more than two years of clinical experience with safinamide we want to retrospectively review its utility as a levodopa saver in our Parkinson's…High dose off-label Safinamide treatment in Young Onset Parkinson’s Disease patients
Objective: To assess tolerability and efficacy of high dose Safinamide treatment in Young Onset Parkinson’s Disease (YOPD) patients with dystonia and history of impulse controls…Safinamide improves motor symptoms severity and daily living in Parkinson’s Disease (PD) patients
Objective: To evaluate the clinical effects of safinamide, administered as add-on therapy to levodopa in fluctuating PD patients, on symptoms severity and daily living. Background:…Opicapone added to safinamide in patients affected by Parkinson’s disease for better controlling motor fluctuations
Objective: The aim of this clinical observation was to verify the sparing of levodopa in patients affected by Parkinson's disease who already started safinamide treatment for…Safinamide: real world evidence in Toledo´s Movement Disorders Unit
Objective: We present a prospective observational-real life study about the use of safinamide in Movement Disorders Unit´s patients. Background: The gold standard of pharmacological treatment…Addition of Opicapone to Safinamide in Parkinson’s Disease patients
Objective: To assess safety and efficacy of Opicapone in patients treated with Levodopa and Safinamide presenting early morning “off” states and akinesia. Background: Safinamide is…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.